Who lung-cancer screening is actually for, and what the trials show it does

Lung cancer is the leading cause of cancer death, and unlike breast, cervical or colorectal cancer it has only one screening test with strong randomised evidence behind it: annual low-dose computed tomography, or LDCT. The evidence is real, and it is also narrow — the test is recommended for a specific, high-risk group and not for the general public. Understanding why requires looking at what the two landmark trials actually measured.

The eligibility rule

The US Preventive Services Task Force recommends annual LDCT screening for adults aged 50 to 80 who have a 20 pack-year smoking history and who currently smoke or have quit within the past 15 years [s1]. A pack-year is one pack a day for one year, so 20 pack-years is met by, for example, a pack a day for 20 years or two packs a day for 10. Screening is meant to stop once a person has not smoked for 15 years, or develops a condition that would prevent curative lung surgery [s1]. This is a B recommendation, the Task Force's grade for a service of moderate net benefit.

Those thresholds were loosened in 2021. The previous 2013 guidance started at age 55 and required a 30 pack-year history [s1]; lowering the bar to 50 and 20 pack-years widened eligibility, in part to reach more women and more Black Americans, who tend to develop lung cancer at lower cumulative exposures. The Task Force reached its conclusion with moderate certainty that screening this population has a moderate net benefit [s1].

What the trials found

The eligibility rules trace directly to two trials. The National Lung Screening Trial enrolled 53,454 people at high risk and randomly assigned them to three annual rounds of either LDCT or chest radiography [s2]. Lung-cancer mortality was 20.0 percent lower in the LDCT group (95% confidence interval 6.8 to 26.7; P=0.004), and death from any cause was 6.7 percent lower [s2]. That result, published in 2011, is the foundation of every lung-screening programme that followed.

The European NELSON trial tested a different design — volume-based LDCT against no screening at all — in 13,195 men, with a smaller group of women analysed separately [s3]. After 10 years, the rate ratio for death from lung cancer was 0.76 among men (95% CI 0.61 to 0.94), a statistically significant reduction; among women the rate ratio was 0.67, though the confidence interval (0.38 to 1.14) crossed one [s3]. In absolute terms, lung-cancer mortality among men was 2.50 deaths per 1,000 person-years with screening against 3.30 without [s3]. Two trials, two designs, the same direction of effect: LDCT finds lung cancers earlier and lets fewer people die of them.

The catch the trials also measured

Screening is not free of harm, and the same papers quantify the cost. In the NLST, 24.2 percent of LDCT scans were positive, against 6.9 percent for radiography — and 96.4 percent of the positive LDCT results were false positives [s2]. A false positive means further scans, sometimes a biopsy, and the anxiety that goes with waiting. NELSON's more selective, volume-based protocol brought that down sharply: only 2.1 percent of participants were referred for a suspicious nodule [s3], which is part of why protocol design matters as much as the decision to screen at all.

This trade-off is exactly why eligibility is restricted to people whose smoking history makes cancer common enough that the benefit outweighs the false alarms. Screen a low-risk population and the arithmetic inverts: almost every positive is false, and the harms dominate.

What it means for a reader

LDCT is the only lung-cancer screening test with randomised mortality evidence, and that evidence is confined to heavy current or former smokers in a defined age band. It is not a general check-up, and it does not replace stopping smoking, which remains the single largest determinant of lung-cancer risk [s1]. Whether a particular person meets the criteria — and whether screening is right given their overall health and life expectancy — is a conversation for a clinician, who can weigh the pack-year history and the harms against the benefit the trials measured. Anyone with a persistent cough, coughing up blood, unexplained weight loss or breathlessness should be assessed regardless of screening status; those are reasons to see a doctor, not to wait for a scheduled scan.

Sources

• [s1] Screening for Lung Cancer: USPSTF Recommendation Statement, JAMA, 2021-03-09
• [s2] Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening (NLST), NEJM, 2011-06-29
• [s3] Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial (NELSON), NEJM, 2020-01-29